2023 World Conference on Lung Cancer (Posters)-EP13.03. Improved Long-Term Survival and Less Chemotherapy in Extended-SCLC Patients: A Real-World Study in the Immunotherapy Era

EP13.03. Improved Long-Term Survival and Less Chemotherapy in Extended-SCLC Patients: A Real-World Study in the Immunotherapy Era - PDF(Abstract)

Back to course

Pdf Summary

This study aimed to evaluate the impact of the introduction of chemoimmunotherapy on the treatment outcomes of extensive-stage small cell lung cancer (ES-SCLC) patients in a real-world setting. The study included all ES-SCLC patients who received platinum-etoposide chemotherapy between November 2017 and March 2023 at a single center in Vicenza, Italy. The effectiveness outcomes analyzed were progression-free survival (PFS), overall survival (OS), and the number of cycles of chemotherapy received. The safety profile of the combination of atezolizumab and chemotherapy was also assessed.<br /><br />Out of the 51 ES-SCLC patients included in the study, 31 received treatment after the authorization of atezolizumab and 20 were treated before. Among those treated after the authorization, 20 were eligible for immunotherapy. Comparing all patients treated after and before July 2020, the median PFS was 5.4 months versus 4.9 months. The median OS was 7.83 months versus 7.01 months. The 12-month OS rate was 23.8% versus 9.8%. Among patients who received chemoimmunotherapy, the median PFS was 6.7 months with a 12-month PFS rate of 24.5%. The median OS was 10.3 months with a 12-month OS rate of 30.5% and a 24-month OS rate of 22.5%.<br /><br />The safety profile of atezolizumab plus chemotherapy was consistent with previous reports, with 5 out of 10 patients experiencing immune-related adverse events and one patient experiencing grade 3-4 autoimmune encephalitis.<br /><br />The study provides evidence of the tolerability and clinical effectiveness of the combination of chemotherapy and immunotherapy in the treatment of ES-SCLC in a real-world setting. It suggests that the addition of immunotherapy may improve survival outcomes and reduce the need for chemotherapy in these patients. However, due to the high heterogeneity in clinical benefit, further research is needed to identify predictive biomarkers for response to chemoimmunotherapy in ES-SCLC patients.

Asset Subtitle

Lorenzo Calvetti

Meta Tag

Speaker Lorenzo Calvetti

Topic SCLC & Neuroendocrine Tumors: First Line Therapy

Keywords

chemoimmunotherapy

extensive-stage small cell lung cancer

real-world setting

platinum-etoposide chemotherapy

progression-free survival

overall survival

number of cycles of chemotherapy

atezolizumab

safety profile

immunotherapy